These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 28448580)
1. Sildenafil normalizes bowel transit in preclinical models of constipation. Sharman SK; Islam BN; Hou Y; Usry M; Bridges A; Singh N; Sridhar S; Rao S; Browning DD PLoS One; 2017; 12(4):e0176673. PubMed ID: 28448580 [TBL] [Abstract][Full Text] [Related]
2. Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome. Sedky AA; Magdy Y Life Sci; 2020 Sep; 256():117960. PubMed ID: 32534033 [TBL] [Abstract][Full Text] [Related]
3. Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice. Islam BN; Sharman SK; Hou Y; Bridges AE; Singh N; Kim S; Kolhe R; Trillo-Tinoco J; Rodriguez PC; Berger FG; Sridhar S; Browning DD Cancer Prev Res (Phila); 2017 Jul; 10(7):377-388. PubMed ID: 28468928 [TBL] [Abstract][Full Text] [Related]
4. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829 [TBL] [Abstract][Full Text] [Related]
5. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate. Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540 [TBL] [Abstract][Full Text] [Related]
6. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Bryant AP; Busby RW; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Pierce CM; Solinga RM; Tobin JV; Mahajan-Miklos S; Cohen MB; Kurtz CB; Currie MG Life Sci; 2010 May; 86(19-20):760-5. PubMed ID: 20307554 [TBL] [Abstract][Full Text] [Related]
7. Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine. Ahsan MK; Tchernychev B; Kessler MM; Solinga RM; Arthur D; Linde CI; Silos-Santiago I; Hannig G; Ameen NA Physiol Rep; 2017 Jun; 5(11):. PubMed ID: 28592587 [TBL] [Abstract][Full Text] [Related]
8. MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux. Tchernychev B; Ge P; Kessler MM; Solinga RM; Wachtel D; Tobin JV; Thomas SR; Lunte CE; Fretzen A; Hannig G; Bryant AP; Kurtz CB; Currie MG; Silos-Santiago I J Pharmacol Exp Ther; 2015 Oct; 355(1):48-56. PubMed ID: 26216942 [TBL] [Abstract][Full Text] [Related]
9. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. Busby RW; Kessler MM; Bartolini WP; Bryant AP; Hannig G; Higgins CS; Solinga RM; Tobin JV; Wakefield JD; Kurtz CB; Currie MG J Pharmacol Exp Ther; 2013 Jan; 344(1):196-206. PubMed ID: 23090647 [TBL] [Abstract][Full Text] [Related]
10. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590 [TBL] [Abstract][Full Text] [Related]
11. Review article: Linaclotide for the management of irritable bowel syndrome with constipation. Layer P; Stanghellini V Aliment Pharmacol Ther; 2014 Feb; 39(4):371-84. PubMed ID: 24433216 [TBL] [Abstract][Full Text] [Related]
12. Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. Sharma S; Sharma T; Dhingra R; Tomar P; Singh S; Malhotra M; Bhardwaj TR Mini Rev Med Chem; 2013 Oct; 13(11):1685-90. PubMed ID: 24001336 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacological and clinical profile of linaclotide (Linzess Keto Y; Kosako M Nihon Yakurigaku Zasshi; 2019; 153(6):289-298. PubMed ID: 31178535 [TBL] [Abstract][Full Text] [Related]
14. Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation. Farmer AD; Ruffle JK; Hobson AR Neurogastroenterol Motil; 2019 Feb; 31(2):e13492. PubMed ID: 30353623 [TBL] [Abstract][Full Text] [Related]
15. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. Johnston JM; Shiff SJ; Quigley EM Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977 [TBL] [Abstract][Full Text] [Related]
16. Cyclic-GMP-Elevating Agents Suppress Polyposis in Sharman SK; Islam BN; Hou Y; Singh N; Berger FG; Sridhar S; Yoo W; Browning DD Cancer Prev Res (Phila); 2018 Feb; 11(2):81-92. PubMed ID: 29301746 [TBL] [Abstract][Full Text] [Related]
17. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome. Love BL; Johnson A; Smith LS Am J Health Syst Pharm; 2014 Jul; 71(13):1081-91. PubMed ID: 24939497 [TBL] [Abstract][Full Text] [Related]